Biopharma merger and acquisition value for the second quarter of 2020 reached $5.9bn, a 14% decline from Q1’s $6.9bn (see Exhibit 1). At the top (making up about a third of this total) was Novo Nordisk AS’s $2.1bn buy of private US biotech Corvidia Therapeutics [See Deal] Novo is paying $725m in cash up front and could provide earn-outs of up to $1.375bn upon the achievement of milestones tied to Corvidia's ziltivekimab, its Phase II candidate for chronic kidney disease. Also see "Novo Nordisk Fortifies Cardio-Renal Efforts With Corvidia Buy" - Scrip, 11 June, 2020.
Dealmaking Quarterly Statistics, Q2 2020
A Look At M&A And Alliance Activity Across The Biopharma, Medical Device And In Vitro Diagnostics Industries, April-June 2020
During Q2 biopharmas reached $5.9bn in merger and acquisition value and drew in $44bn in potential deal value from alliances. Device company M&A values reached $159m, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $1.4bn.
